Synlogic is a clinical-stage biopharmaceutical company focused on improving its proprietary drug discovery and development platform to create Synthetic Biotic medicines. Synthetic Biotic medicines are designed to be programmed to metabolize, or consume, a toxic substance, compensate for damaged metabolic pathways in patients, or produce one or more therapeutic factors. Co.'s primary product candidate for the treatment of metabolic dysfunction is SYNB1618, an oral therapy intended for the treatment of phenylketonuria. Co.'s Synthetic Biotic clinical immuno-oncology candidate is SYNB1891, a Synthetic Biotic medicine engineered to act as a dual innate and adaptive immune activator. The SYBX stock yearly return is shown above.
The yearly return on the SYBX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SYBX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|